Search

Displaying results 2701 - 2710 of 6835 in total
  1. Drug

    Methyl aminolevulinate

    go.drugbank.com/drugs/DB00992
    ApprovedInvestigational

    Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.

  2. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.

  3. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    be 41% compared to 8% with the placebo. … Desmoid tumors are typically characterized by aberrant activation in Notch signaling.

  4. Drug

    Pirenzepine

    go.drugbank.com/drugs/DB00670
    ApprovedWithdrawn

    It is generally well tolerated by patients. … It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence.

  5. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). … In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]

  6. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022].

  7. Drug

    Pyrimethamine

    go.drugbank.com/drugs/DB00205
    ApprovedInvestigationalVet approved

    One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

  8. Drug

    Bromothalonil

    go.drugbank.com/drugs/DB14199
    Approved

    In 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326]. … Sensitivity to Bromothalonil may be identified with a clinical patch test.

  9. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] … [A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience.

  10. Drug

    Amineptine

    go.drugbank.com/drugs/DB04836
    ApprovedIllicitWithdrawn

    The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome